Our Partners | Transpharmation

Clerkenwell Health is an innovative, UK-based mental health start-up building a platform to accelerate patients’ access to a range of psychedelic-assisted therapies over the coming years. Clerkenwell is focused on helping its clients generate the clinical data required to mainstream these exciting treatment methodologies with doctors and regulators alike.

The team is led by CEO Tom McDonald, a former Accenture pharmaceutical specialist with a focus on patient-centric care and CSO Dr Henry Fisher, a chemist and drug policy expert. Patient therapy is led by Dr Sara Tai, a clinical psychologist, a Senior Lecturer in Clinical Psychology at the University of Manchester and an expert in psychotherapy in clinical trials of psychedelic medicine.

A key partner for Transpharmation is Agenda Life Sciences, (ALS) who work with us at Discovery Park, Kent. ALS supports us with day-to-day operations, governance and assurance of strict regulation, as well as ethical compliance with the Home Office for experiments.

They are one of only 14 establishments to hold the globally recognised AAALAC accreditation assuring Transpharmation’s clients of scientific validity and reliable, robust scientificoutcomes.

“Comorbidity of chronic pain and mood disorders: breaking the vicious cycle” - this is the aim of the HaPpY grant from Innovative Training Networks, who have assembled a world-class team of behavioural neuroscientists, electrophysiologists, molecular biologists, neuropharmacologists and clinicians specializing in pain and/or mood disorders from academic research labs and hospitals along with experts from the non-academic sector. Transpharmation is delighted to have been invited to join as well-known experts in this therapeutic area and we look forward to delivering training to young scientists.

Blue Oak drug hunters are experts in the systems neurobiology of brain disorders, medical chemistry and informatics. Their leading productivity integrates a global research team with cutting edge technologies in behavioural profiling, synthetic chemistry and brain imaging.

The University of Hertfordshire and Transpharmation undertake collaborative research projects and co-fund / co-supervise PhD studentships, combining the expertise of research scientists from both organisations to further capabilities and develop new assays.

Varsity BioLogistics support to the global pharmaceutical, healthcare, life science & CRO industries.

Metris provide Innovative solutions, instruments and software for animal behaviour research.

BonePain II is a European training network promoting innovation and education within bone pain research. The BonePain II network encompasses 8 academic groups and 4 industries all committed to creating an outstanding training programme for early stages researchers to elucidate the mechanisms of bone pain and develop new medicines.

The Brain Involvement iN Dystrophinopathies (BIND) consortium, which in 2020 kickstarted a €6M+ EU-funded international project, will undoubtedly play a key role in upcoming years. As a member of the BIND consortium, Transpharmation Ireland’s involvement in this project is twofold: we are contributing first to characterising DMD genetic animal models replicating human mutations severely affecting brain function, and secondly to testing the efficacy of second-generation exon skipping approaches in rescuing cognitive-affective abnormalities observed in these models. Ultimately, our efforts will allow identifying clinically translatable therapeutic options offering a robust improvement of both mental and physical well-being for DMD patients.

Direct Pathways is a consultancy firm who support businesses to work more efficiently and focus on the building blocks for growth and increased profitability. We have worked with them to improve business performance by tightening our core structures and empowering our people to be more effective.